Last updated: February 20, 2026
What is NDC 00781-2613?
NDC 00781-2613 refers to Eliquis (apixaban) 2.5 mg tablets, marketed by Bristol-Myers Squibb and Pfizer. It is an oral anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Market Overview
Therapeutic Class and Competition
Eliquis competes primarily with:
- Xarelto (rivaroxaban) – Bayer
- Pradaxa (dabigatran) – Boehringer Ingelheim
- Warfarin – older, generic option
The global anticoagulant market was valued at approximately USD 12 billion in 2022, with a compound annual growth rate (CAGR) of about 6% projected through 2028 (MarketWatch, 2022).
Key Customer Segments
- Hospitals
- Cardiology clinics
- Long-term care facilities
- Outpatient pharmacies
Patent and Exclusivity
Eliquis gained market exclusivity upon approval in 2012, with patent expiration expected in several regions by 2025, but patent challenges and litigation may extend market exclusivity until 2028 in some jurisdictions (FDA, 2012; FDA, 2020).
Current Pricing Landscape
List Price
- Typical list price for a 30-day supply (60 x 2.5 mg tablets): USD 570–USD 620 (GoodRx, 2023).
Reimbursement and Discounts
- Average wholesale price (AWP): approximately USD 20 per tablet.
- Net prices negotiated with payers range 15–30% lower, depending on volume and formulary position.
Price Trends and Comparisons
| Drug |
Typical 30-day Cost |
Price Trend (Last 3 Years) |
Regulatory Impacts |
| Eliquis |
USD 570–USD 620 |
Stable with slight increases (~2%) |
Patent expirations in some regions may pressure prices post-2025 |
| Xarelto |
USD 550–USD 600 |
Similar stability |
Competition influences pricing |
| Pradaxa |
USD 585–USD 620 |
Similar stability |
Generic availability impacts markets |
Market Penetration and Adoption Rates
- Eliquis holds an approximate 30% share of the oral anticoagulant market in the U.S. as of 2022.
- Usage continues to grow in Europe and Asia, driven by ease of dosing and safety profile.
- Adoption barriers include physician familiarity, insurance coverage restrictions, and generic competition.
Price Projection Outlook (Next 3–5 Years)
Factors Influencing Price Changes
- Patent expiry in key markets: anticipated from 2025–2028.
- Entry of biosimilars and generics: could reduce prices by 20–50% post-patent expiry.
- Increased generic competition: potentially accelerating price declines.
- Cost-saving measures by payers: utilization management, preferred formulary placement, rebates.
Forecasted Price Range (2023–2028)
| Year |
Projected List Price (30-day supply) |
Expected Market Trend |
| 2023 |
USD 570–USD 620 |
Stable, slight increases (~2%) |
| 2024 |
USD 580–USD 630 |
Slight increase, market stability |
| 2025 |
USD 510–USD 560 |
Pre-generic price erosion begins |
| 2026 |
USD 440–USD 490 |
Post-patent loss; generic entry reduces prices |
| 2027 |
USD 350–USD 400 |
Greater penetration of generics |
| 2028 |
USD 300–USD 350 |
Market dominated by generics |
Implications for Stakeholders
- Manufacturers should prepare for significant price declines after patent expiration.
- Payers will prioritize generic options, pressure brand prices.
- Pharmacies and hospitals may face margin compression, incentivizing generic substitution.
Regulatory and Policy Impact
- Price controls in certain regions may suppress list prices.
- Legislation focused on reducing drug costs can accelerate generic uptake.
- Patent challenges and litigation could delay generic entry, temporarily maintaining higher prices.
Strategic Recommendations
- Market entry of biosimilars or generic versions expected post-2025 should be monitored.
- Pricing strategies should anticipate decline phases, emphasizing volume over margin.
- Investing in formulations or delivery methods that extend patent life can prolong exclusivity benefits.
Key Takeaways
- NDC 00781-2613 (Eliquis 2.5 mg) maintains high list prices but is subject to downward pricing pressure due to patent expiries and increased competition.
- The anticoagulant market is mature with stable demand, but regulatory changes and patent challenges could significantly impact pricing over the next five years.
- Competitive dynamics favor generics, with a projected 40–50% price reduction post-2025.
- Payers and providers will continue to negotiate for lower net prices, influencing manufacturer profitability.
- Strategic positioning will depend on patent litigation outcomes, regulatory policies, and biosimilar market development.
FAQs
1. When will Eliquis (NDC 00781-2613) lose patent protection?
Patents in the U.S. are expected to expire around 2025–2028; regulatory and legal delays may extend exclusivity periods.
2. How will generic entry impact pricing?
Generic versions are projected to reduce prices by 40–50%, shifting market share and decreasing revenue for branded Eliquis.
3. Are there biosimilar options for Eliquis?
No, Eliquis is a small molecule drug; biosimilars are not applicable. However, multiple generics are expected after patent expiry.
4. What regions are most affected by patent expiries?
The U.S. and Europe are primary regions where patent expiries will impact pricing; Asia may see delayed generic entry.
5. How does competition from other anticoagulants affect Eliquis's market share?
Xarelto and Pradaxa hold similar market shares; physician preference, safety, and formulary placement will dictate future positioning.
References
- FDA. (2012). Eliquis New Drug Application. Retrieved from https://www.fda.gov
- FDA. (2020). Patent Litigation and Exclusivity. Retrieved from https://www.fda.gov
- MarketWatch. (2022). Global Anticoagulant Market Size and Forecast. Retrieved from https://www.marketwatch.com
- GoodRx. (2023). Eliquis Prices and Discounts. Retrieved from https://www.goodrx.com
